CannTab Therapeutics (CSE:PILL) CEO Jeff Renwick and Chief Financial officer Richard Goldstein sat down with Steve Darling from Proactive Investors at the LD Microcap conference in Los Angeles to talk about their company and their slow release tablets. They also chatted about the U.S. market and the potential for growth.
viewCanntab Therapeutics Ltd
Canntab Therapeutics hoping to bring their slow release tablet tech to U.S.
Quick facts: Canntab Therapeutics Ltd
Price: - -
CSE:PILL
Market: CSE
Market Cap: -
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Health
Genprex wins FDA Fast Track status for its Oncoprex therapy in combination...
4 days, 23 hours ago
Industry & services
Tesla value tops $100bn setting Elon Musk up for US$346mln pay day
3 days, 23 hours ago
